Associate Research Scientist
Clinical Development and Product Supervisor
Cancer Immunotherapy Laboratory and the
Blood and Stem Cell Transplantation Programs
Adele R. Decof Cancer Center
Roger Williams Medical Center-
North Campus G05
825 Chalkstone Avenue
Providence, RI 02908
(401)456-5783 tel.
(401)456-2398 fax
Ongoing Breast Cancer Immunotherapy Clinical Trials at RWMC:
Ongoing Prostate Cancer Immunotherapy Clinical Trials at RWMC:
Phase I/II Study of Immunotherapy With Armed Activated T Cells, Interleukin-2, and Sargramostim (GM-CSF) in Men with Hormone Refractory Prostate Cancer
Non-Hodgkin's Lymphoma (NHL) Immunotherapy Clinical Trials at RWMC:
Immune Consolidation with Activated T Cells Armed with OKT3 x Rituxan (anti-CD3 x anti-CD20) Bispecific Antibody after Peripheral Blood Stem Cell Transplant for High Risk CD20+ Non-Hodgkin’s Lymphomas
Additional Abstracts (Listed Chronologically) ...
1. Beitz, J., Davol-Lewis, P., Clark, J., Kato, J., Medina, M., Frackelton, A.R. Jr., Lappi, D.A., Baird, A., and Calabresi, P. Inhibitory effects of the mitotoxin, FGF-SAP, on human melanoma growth in vitro and in vivo. Minisymposium Presentation at the Annual meeting of the American Federation of Clinical Research, 1991.
2. Beitz, J., Davol-Lewis, P., Clark, J., Kato, J., Medina, M., Frackelton, A.R. Jr., Lappi, D.A., Baird, A., and Calabresi, P. Inhibitory effects of the mitotoxin, FGF-SAP, on human melanoma growth in vitro and in vivo. Poster Presentation at the Annual New York Academy of Sciences, 1991.
3. Beitz, J., Davol-Lewis, P., Clark, J., Kato, J., Medina, M., Frackelton, A.R. Jr., Lappi, D.A., Baird, A., and Calabresi, P. Inhibitory effects of the mitotoxin, bFGF-SAP, on human ovarian carcinoma in vitro and in vivo. Minisymposium Presentation at the 82nd Annual meeting of the American Association for Cancer Research, 1991.
4. Beitz, J., Davol-Lewis, P., Clark, J., Kato, J., Medina, M., Frackelton, A.R. Jr., Lappi, D.A., Baird, A., and Calabresi, P. Inhibitory effects of a saporin mitotoxin on human neuroblastoma growth in vitro and in vivo. Minisymposium Presentation at the Annual meeting of the American Federation of Clinical Research, 1991.
5. Beitz, J., Davol, P.A., Frackelton, A.R. Jr., Clark, J., Lappi, D.A., and Baird, A. Serial low-dose injections increase in vivo antitumor efficacy of basic fibroblast growth factor-saporin mitotoxin against human ovarian teratocarcinoma. Poster Presentation at the 83rd Annual meeting of the American Association for Cancer Research, 1992.
6. Beitz, J., Davol, P.A., Darnowski, J.W., Lappi, D.A., and Baird, A. Combination of FGF-SAP mitotoxin and cisplatin in the treatment of human melanoma. Poster-Discussion Presentation at the 84th Annual meeting of the American Association for Cancer Research, 1993.
7. Beitz, J., Davol, P.A., Darnowski, J.W., Lappi, D.A., and Baird, A. Anti-tumor activity of basic FGF-SAP mitotoxin. Poster Presentation at the Cell Signalling and Cancer Treatment Conference, 1993.
8. Davol, P.A., Beitz, J., Frackelton, A.R. Jr., Lappi, D.A., and Baird, A. Development of FGF-SAP mitotoxin resistance in a sensitive human melanoma cell line. Poster Presentation at the 84th Annual meeting of the American Association for Cancer Research, 1993.
9. Davol, P.A., Mohler, M., Cook, J., and Frackelton, A.R. Jr. Antitumor activity of the recombinant mitotoxin, basic fibroblast growth factor-saporin, against human breast carcinoma cell, MCF-7, conferred by mechanisms operative only in vivo. Poster Presentation at An International Cancer Research Symposium: New Approaches in the Therapy of Breast Cancer, 1994.
10. Beitz, J., Davol, P.A., Ying, W., Martineau, D., Maher, P., Lappi, D.A., and Baird, A. In vivo activity on ovarian teratocarcinoma of 11A8-Saporin, an immunotoxin which targets basic fibroblast growth factor receptors. Poster Presentation at the Antibody Immunoconjugates and Radiopharmaceuticals Conference, 1994.
11. Davol, P.A., Beitz, J., Frackelton, A.R. Jr., Lappi, D.A., and Baird, A. Suramin restores sensitivity to basic fibroblast growth factor-saporin mitotoxin in a resistant human melanoma cell line in vitro. Poster Presentation at the 85th Annual meeting of the American Association for Cancer Research, 1994.
12. Davol, P.A., Mohler, M., Cook, J. and Frackelton, A.R. Jr. Therapeutic evaluation of recombinant basic fibroblast growth factor-saporin for targeting mammary carcinoma in vitro and in vivo. Poster Presentation at the 86th Annual meeting of the American Association for Cancer Research, 1995.
13. Davol, P.A. and Frackelton, A.R. Jr. Enhancement by suramin of recombinant basic fibroblast growth factor-saporin antitumor activity against human melanoma in vivo. Poster Presentation at the 86th Annual meeting of the American Association for Cancer Research, 1995.
14. Darnowski, J.W., Davol, P.A., Ahsanuddin, A.N., and Goulette, F.A. Resistance to azidodeoxythymidine in HCT-15 cells reflects altered DNA repair processes and is associated with increased wild-type p53 expression. Poster Presentation at the 86th Annual meeting of the American Association for Cancer Research, 1995.
15. Davol, P.A., Goulette, F.A., and Darnowski, J.W. Modulation of p53 by human recombinant interferon alpha-2a and its effects on cisplatin resistance in a human melanoma cell line. Minisymposium Presentation at the 87th Annual meeting of the American Association for Cancer Research, 1996.
16. Davol, P.A. and Frackelton, A.R. Jr. Targeting prostatic carcinoma with a saporin toxin directed to basic fibroblast growth factor receptors. Poster Presentation at the 87th Annual meeting of the American Association for Cancer Research, 1996.
17. Darnowski, J.W., Davol, P.A., and Goulette, F.A. Human recombinant interferon alpha-2a disrupts polymerase beta-mediated DNA repair to sensitize HCT-8 cells to the DNA damaging agent azidothymidine. Poster Presentation at the 87th Annual meeting of the American Association for Cancer Research, 1996.
18. Davol, P.A., Goulette, F.A., Frackelton, A.R. Jr., and Darnowski, J.W. Association of p53 protein with DNA polymerase beta in human melanoma: Evidence for a role in p53-regulated G1 arrest in response to DNA damage. Minisymposium Presentation at the 88th Annual meeting of the American Association for Cancer Research, 1997.
19. Davol, P.A. and Frackelton, A.R., Jr. Reduced receptor binding in human prostatic tumors made resistant in vivo to a basic fibroblast growth factor receptor-directed toxin. Poster Presentation at the 88th Annual meeting of the American Association for Cancer Research, 1997.
20. Darnowski, J.W., Leith, J.T., Goulette, F.A., Davol, P.A., and Calabresi, P. Human recombinant interferon alpha-2a enhances the cytotoxicity of ionizing radiation in DU 145 human prostate carcinoma cells. Poster Presentation at the 88th Annual meeting of the American Association for Cancer Research, 1997.
21. Davol, P.A. and Frackelton, A.R. Jr. The PI-3-kinase inhibitors, wortmanin and LY294002, enhance cytotoxicity of receptor-directed toxin chimeras in vitro and in vivo. Poster Presentation at the 89th Annual meeting of the American Association for Cancer Research, 1998.
22. Davol, P.A. and Frackelton, A.R. Jr. Enhanced antitumor activity and circumvention of suramin-related toxicity in modality therapy combining suramin and an FGF receptor-directed-toxin chimera in a human melanoma animal model. Poster Presentation at the 90th Annual meeting of the American Association for Cancer Research, 1999.
23. Davol, P.A. and Frackelton, A.R. Jr. Development and characterization of state-specific antibodies recognizing only activated, tyrosine-phosphorylated Shc. Poster Presentation at the 91st Annual meeting of the American Association for Cancer Research, 2000.
24. Davol, P.A. and Frackelton, A.R. Jr. In situ detection of tyrosine-phosphorylated Shc protein as an Indicator of growth factor receptor-activation in breast cancer cells. Poster Presentation at the 91st Annual meeting of the American Association for Cancer Research, 2000.
25. Davol, P.A. and Frackelton, A.R. Jr. Development and characterization of state-specific antibodies recognizing only activated, tyrosine-phosphorylated Shc. Proc.AACR 2000 #1332.
26. Davol, P.A. and A. R. Frackelton, Jr. Requirement for Shc Phosphorylation in Insulin-like Growth Factor-1 Signaling to Mitogen-Activated Protein Kinase Through the Epidermal Growth Factor Receptor in the Prostate Adenocarcinoma Cell Line PC-3. Proc.AACR 2001#5156.
27. Smith, J., Davol, P., Kouttab, N., Rathore, R., Elfenbein, G.J., Lum, L.G..Anti-CD3 x Anti-HER2/neu Armed T cells Inhibit Tumor Development or Induced Remissions in Prostate Cancer Bearing Beige/SCID Mice. Experimental Hematology 30:159A, 2002.
28. Lum, L., Davol, P., Grabert, R., Kouttab, N., Frackelton, A.R., Rathore, R. Targeting Pancreatic Cancer with Armed Activated T cells directed at Her2/neu receptors. Experimental Hematology 30:77A, 2002 .
29. Davol, P.A., Bagdasaryan, R., Frackelton, A.R. Jr. Shc adapter proteins in breast cancer prognosis: novel molecular markers that predict aggressive Stage 1 tumors. Proc.AACR 2002 #221
30. Williamson, L.R., Davol, P.A., Frackelton, A.R.Jr. The 66-kDa Shc protein inhibits tumorgenicity. Department of Defense Era of Hope Conference (Tumor Suppressor Genes), 2002.
31. Frackelton, A.R. Jr. and Davol, P.A. Shc proteins are prognostic indicators. Department of Defense Era of Hope Conference (Prognostic Indicators), 2002.
32. Davol PA, Bagdasaryan R, Frackelton, Jr. AR. Shc adapter proteins as prognostic markers in patients with node negative breast cancer. San Antonio Breast Cancer Symposium 2002 # 145.
33. Davol PA, Olson S, Gall J, Grabert R, Kouttab N, Lum LG. Trafficking and Clinical Responses in SCID-Beige Mice Bearing Her2/Neu-Positive Tumors Treated with Her2Bi-Retargeted Anti-CD3 Activated T Cells (ATC). Annual Meeting of the International Society for Biological Therapy, Oct 30-Nov 2, 2003.
34. Gall, J.M., Grabert, R.C., Deavers, M., Davol, P.A., and Lum, L.G. Targeting CD20+ Rituxan Resistant B-Cells with Anti-CD3 Activated T cells (ATC) Armed with anti-CD3 x anti-CD20 (CD20Bi). Annual Meeting of the International Society for Experimental Hematology, 32(7S):19A, 2004.
35. Lum, L.G., Davol, P.A., Sievers, R.E., Grabert, R.C., Gall, J.M.,Yee, M.S., Maizel. A.L., Larrick, J.W., Lee, R.J. Bispecific Antibodies Directed at Injury-Specific Adhesion Molecules Enhance Homing of Human Cells to Myocardial Infarctions in a Xenogeneic Rat Model. Annual Meeting of the International Society for Experimental Hematology, 32(7S):22A, 2004.
36. Lee, R.J., Davol, P.A., Fang, Q., Sievers, R., Yee, M., Grabert, R.C., Larrick, J., Lum, L.G. Targeting of Human Stem Cells to Myocardial Infarctions in a Xenogeneic Rat Model. Annual Meeting of the Biomedical Engineering Society, October 14, 2004.
37. Olson, S., Davol, P.A., Lum, L.G. Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 x Anti-EGFR.
38. Davol, P.A., Gall, J.M., Grabert, R.C., Young, W.B., Cummings, F.J., Rathore, R., Colvin, G.A., Elfenbein, G.J., Lum, L.G. Infusions of T Cells Armed with anti-CD-3 x anti-Her2/neu Bispecific Antibody Modulate In Vivo Patient Immune Responses in Phase I Clinical Trials for Breast and Hormone Refractory Prostate Cancers. Blood 104(11):379a, 2004.
39. Lum, L.G., Davol, P.A., Sievers, R.E., Grabert, R.C., Fang, Q, Gall, J.M., Yee, M.S., Larrick, J.W., Lee, R.J. Human Stem Cells Armed with Bispecific Antibodies Home to Injury-Specific Molecules in Myocardial Infarcts in Nude Rats. Blood 104(11):736a, 2004.
40. Lee, R.J, Fang, Q., Davol, P.A., Sievers, R.E., Yee, M.S., Grabert, R.C., Gall, J.M., Larrick, J.W., Lum, L.G. Systemic Delivery of Human Stem Cells Targeted to Myocardial Infarctions in a Xenogeneic Rat Model. Circulation 2005 (in press).
41. Reusch, U., Olson, S., Davis, J., Davol, P., Sundarum, M.,
Liu, L., Lum, L.G. T-Cell Based Cancer
Immunotherapy with
a Bispecific Antibody Directed at CD3 and EGFR. ASCO 2005 (in press).